Insulin Icodec (Awiqli)
Status: FDA-approved for adults with Type 2 Diabetes; not US-approved for Type 1 Diabetes
Brand / generic: Awiqli / insulin icodec-abae
Sponsor: Novo Nordisk
US regulatory source: BLA/NDA 761326 approval letter + US prescribing information
Vault role: substance hub for once-weekly basal insulin and Vitals CGM coaching implications
TL;DR
Insulin icodec (Awiqli) is a once-weekly basal insulin analog. Its practical advantage is convenience: one basal injection per week instead of daily basal injections. Mechanistically, it combines reduced insulin-receptor affinity with a C20 fatty-diacid albumin-binding depot, producing a roughly week-long PK/PD profile. The ONWARDS program supports non-inferior HbA1c lowering versus daily basal insulins, with small average HbA1c advantages in some analyses and a CGM time-in-range signal in ONWARDS 1. The tradeoff is not subtle: clinically significant hypoglycemia rates are higher in pooled T2D analyses, and ONWARDS 6 showed a stronger hypoglycemia penalty in T1D. For Vitals, this is mainly a CGM/TIR and safety-window note, not a performance or longevity intervention.
Why it matters for Vitals
Insulin icodec matters when a Vitals client is already using, switching to, or being evaluated for basal insulin. It changes the monitoring cadence and creates a specific weekly safety pattern.
- CGM / TIR: ONWARDS 1 CGM analyses found roughly 4–5 percentage points higher time-in-range versus glargine U100; this is directly monitorable with CGM and more actionable than broad HbA1c claims. [PMID:37356066; PMID:39374601]
- Hypoglycemia timing: the main coaching risk is elevated low-glucose risk after dosing, especially the reported day-2-to-4 post-injection window; this should drive review timing and low-glucose alert sensitivity.
- Weekly cadence: injection day can anchor weekly CGM review, medication adherence check, weigh-in, and clinician-supervised titration review.
- Body composition / weight: insulin-mediated weight gain remains relevant; ONWARDS 2 showed greater weight gain than degludec. [PMID:37148899]
- Boundary: do not present icodec as a GLP-1, weight-loss drug, CV-risk reducer, or generalized metabolic optimization tool.
Human clinical oversight is required for any insulin dose, titration, or hypoglycemia-response protocol.
Key facts
| Domain | Current vault summary |
|---|---|
| Class | Long-acting basal insulin analog for once-weekly subcutaneous injection |
| Mechanism | A14E/B16H/B25H substitutions + desB30 deletion reduce insulin-receptor affinity; C20 fatty diacid at LysB29 creates reversible albumin binding. [PMID:34413118; PMID:33944562] |
| Half-life | Designed around ~196 h; clinical/source estimates commonly fall around ~155–196 h depending on method. [PMID:33944562; PMID:34413118] |
| US indication | Adults with Type 2 Diabetes; not US-approved for T1D. |
| Device / formulation | U-700 FlexTouch prefilled pen; no vials/cartridges; once weekly on the same day each week. |
| Label dosing anchor | FDA label: insulin-naive weekly starting dose 70 units; switching from daily basal requires label-specific conversion and close glucose monitoring. |
| Clinical program | ONWARDS 1–6 phase 3 program; T2D trials support non-inferior HbA1c lowering. |
| TIR signal | ONWARDS 1 CGM: about +4–5 pp TIR versus glargine U100. [PMID:37356066; PMID:39374601] |
| Hypoglycemia | Pooled ONWARDS 1–5: higher event rate for clinically significant/severe hypoglycemia, RR 1.51. [PMID:38951942] |
| T1D boundary | ONWARDS 6: non-inferior HbA1c but higher level 2/3 hypoglycemia versus degludec; this is central to the US non-approval for T1D. [PMID:37863084] |
| Weight | Modest gain signal; ONWARDS 2 ETD +1.70 kg vs degludec. [PMID:37148899] |
| Patient experience | PRO analyses favor once-weekly treatment satisfaction and injection-burden reduction. [PMID:39368488] |
Mechanism summary
Icodec is not a new glucose-lowering pathway. It is insulin with engineered pharmacokinetics.
What was engineered
- Reduced insulin-receptor affinity: A14E, B16H, and B25H substitutions reduce receptor binding/clearance so the molecule does not behave like rapid native insulin. [PMID:34413118]
- Albumin-binding depot: a C20 fatty diacid side chain at LysB29 reversibly binds human serum albumin, leaving most circulating drug depot-bound and slowly released. [PMID:34413118]
- Long half-life: the combined lower receptor affinity + albumin binding produces approximately week-long exposure and supports once-weekly dosing. [PMID:33944562]
- Same final signaling: once free drug binds the insulin receptor, downstream insulin signaling remains the relevant effect; the innovation is exposure-shaping, not a new receptor biology.
This is an instance of Albumin Binding Half-Life Extension, a reusable PK strategy also relevant to some long-acting peptides and acylated metabolic drugs.
Practical interpretation
The flat weekly profile reduces injection frequency, but it also makes dose mistakes or hypoglycemia harder to rapidly unwind than with shorter-acting insulin. The FDA label specifically emphasizes close glucose monitoring when switching from daily basal insulin and warns that long action can delay recovery from hypoglycemia.
What the current evidence suggests
Efficacy is credible but modest
The strongest interpretation of the ONWARDS program is non-inferior basal insulin efficacy with convenience benefits, not broad superiority.
- ONWARDS 1: insulin-naive T2D; icodec was non-inferior and statistically superior to glargine U100 for HbA1c at 52 weeks; CGM TIR favored icodec by about 4–5 pp. [PMID:37356066; PMID:39374601]
- ONWARDS 2: basal insulin-experienced T2D; icodec was non-inferior/superior to degludec for HbA1c, but with greater weight gain and numerically higher hypoglycemia. [PMID:37148899]
- ONWARDS 3: insulin-naive T2D; non-inferior/superior HbA1c versus degludec; level 2/3 hypoglycemia signal was higher early and attenuated depending on analysis window. [PMID:37354562]
- ONWARDS 4: basal-bolus T2D; icodec replaced basal insulin only and remained paired with mealtime insulin aspart; HbA1c was non-inferior to daily basal comparator. [PMID:37156252]
- ONWARDS 5: pragmatic/self-titration context; once-weekly icodec with dose guidance improved HbA1c versus daily basal analogs in the trial setting. [PMID:37748181]
- Pooled ONWARDS 1–5: participant-level analysis found higher clinically significant/severe hypoglycemia event rates despite broadly similar incidence. [PMID:38951942]
T1D is the cautionary boundary
ONWARDS 6 in adults with T1D confirmed HbA1c non-inferiority, but level 2/3 hypoglycemia was significantly higher with icodec versus degludec. This is why the US note must keep T1D out of the practical indication frame. [PMID:37863084]
Likely wearable / Vitals relevance
CGM time-in-range
- Best evidence-backed signal: TIR improved in ONWARDS 1 CGM analyses. [PMID:37356066; PMID:39374601]
- Vitals use: weekly CGM reports can compare pre-switch versus post-switch TIR, time-below-range, overnight lows, and coefficient of variation.
- Boundary: ONWARDS was not a Vitals/wearable coaching study. Treat this as clinical CGM evidence translated into coaching support, not a validated Vitals protocol.
Day-2-to-4 hypoglycemia window
- Icodec users should be treated as having a predictable weekly risk window after injection.
- Vitals review logic should highlight lows or near-lows occurring in that window, especially nocturnal lows.
- Low-glucose events should prompt clinician review of dose/titration, food intake, exercise, alcohol, renal function, and concurrent glucose-lowering drugs.
Fasting glucose variability
The flat PK profile may reduce some day-to-day basal-coverage variability, but the meaningful question is not “is the curve elegant?” It is whether the person’s CGM shows better TIR without more time-below-range. Link this to Glycemic Variability and Glucose Variability Detection Model rather than inventing an icodec-only metric.
HRV / recovery confounds
Hypoglycemia can alter sleep, autonomic tone, awakenings, perceived recovery, and next-day readiness. HRV changes are nonspecific; if low glucose is present, glucose safety outranks recovery-score interpretation.
Risks and uncertainty
Primary risk: hypoglycemia
- Pooled ONWARDS 1–5 T2D: clinically significant/severe hypoglycemia event rate RR 1.51 versus daily basal comparators. [PMID:38951942]
- ONWARDS 6 T1D: RR 1.90 versus degludec for level 2/3 hypoglycemia. [PMID:37863084]
- FDA label: do not use during hypoglycemia; switching from daily basal requires close glucose monitoring; long action may delay recovery.
Weight gain
Insulin is not weight-loss therapy. ONWARDS 2 found greater weight gain with icodec versus degludec, and pooled summaries suggest modest weight gain versus daily basals. [PMID:37148899]
Immunogenicity
Anti-drug antibodies were common in trials, with no clear clinical effect on safety/effectiveness in the trial populations. Long-term real-world significance remains uncertain.
Long-term and real-world gaps
- No mature multi-year real-world adherence/persistence evidence at approval.
- No dedicated Vitals/wearable clinical trial.
- No demonstrated cardiovascular benefit; avoid CV-risk-reduction claims.
- Pediatric use and US T1D use remain outside the current practical US frame.
- Cost/formulary access may dominate real-world uptake.
Best stack context
This is a medical basal-insulin option, not a supplement stack element.
- With GLP-1 / incretin agents: clinically plausible when prescribed; GLP-1 agents may counter insulin-associated weight gain, but GI tolerability, hypoglycemia risk, and clinician-led dose changes matter.
- IcoSema context: fixed-ratio icodec + semaglutide is relevant internationally/pipeline-wise, but the vault should not imply US availability unless source status changes.
- With SGLT2 inhibitors / metformin / sulfonylureas: additive glucose-lowering can change hypoglycemia risk and requires clinician oversight.
- Exercise / fasting / alcohol: all can shift glucose needs; CGM lows around these contexts should not be attributed to icodec alone without review.
What stays inside this hub
The following do not currently need standalone vault notes:
- ONWARDS trial-by-trial minutiae beyond key outcomes and PMIDs.
- Awiqli pen logistics, storage rules, and dose-conversion tables; these belong in the FDA label and clinician workflow.
- Icodec-specific amino acid substitutions as a separate mechanism note; they are too product-specific.
- A dedicated “icodec detection model”; existing Glycemic Variability, CGM Glucose Patterns Non-Diabetic, and Glucose Variability Detection Model are the reusable CGM graph nodes. The icodec-specific day-2-to-4 signal stays here unless weekly basal insulin monitoring becomes a broader class protocol.
Claims to avoid
- “Lower hypoglycemia than daily basal insulin” — pooled event rates are higher. [PMID:38951942]
- “Approved for T1D in the US” — it is not.
- “Weight loss” or “weight neutral” without qualification — insulin-associated weight gain remains relevant. [PMID:37148899]
- “Cardiovascular benefit” — not supported.
- “Eliminates mealtime insulin” — basal-bolus patients still require prandial insulin when clinically indicated. [PMID:37156252]
- “Proven real-world adherence advantage” — PRO preference is not the same as long-term real-world persistence. [PMID:39368488]
Related notes
- Albumin Binding Half-Life Extension — reusable PK strategy behind icodec’s weekly exposure.
- Glycemic Variability — glucose fluctuation and coefficient-of-variation interpretation.
- Glucose Variability Detection Model — CGM interpretation logic; not an insulin-specific dosing model.
- CGM Glucose Patterns Non-Diabetic — CGM pattern framework; useful contrast because icodec users are clinical insulin users, not wellness-only CGM users.
- Metabolic Flexibility — broader metabolic interpretation; avoid conflating insulin therapy with improved metabolic flexibility.
- GLP-1 GIP Glucagon — incretin receptor context for GLP-1 co-therapy and IcoSema comparisons.
- SGLT2 Inhibitors, Metformin Longevity, Berberine — other glucose/metabolic agents that can complicate interpretation or hypoglycemia risk.
- Substances MOC — non-peptide substance index.
Source anchors
- FDA Awiqli approval letter and US Prescribing Information, BLA/NDA 761326.
- Molecular characterization / albumin-binding PK: PMID:34413118; PMID:33944562.
- ONWARDS 1: PMID:37356066; CGM analysis: PMID:39374601.
- ONWARDS 2: PMID:37148899.
- ONWARDS 3: PMID:37354562.
- ONWARDS 4: PMID:37156252.
- ONWARDS 5: PMID:37748181.
- ONWARDS 6: PMID:37863084.
- ONWARDS 1–5 pooled hypoglycemia/efficacy: PMID:38951942.
- Patient-reported outcomes / treatment satisfaction: PMID:39368488.